Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease (Q35650273)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 2011

Language	Label	Description	Also known as
English	Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease	scientific article published on December 2011

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

based on heuristic

inferred from title

author name string

Geoffrey L Ray

1

1 reference

Europe PubMed Central

9 August 2017

Kwamena E Baidoo

2

1 reference

Europe PubMed Central

9 August 2017

Lanea M M Keller

3

1 reference

Europe PubMed Central

9 August 2017

Paul S Albert

4

1 reference

Europe PubMed Central

9 August 2017

Martin W Brechbiel

5

1 reference

Europe PubMed Central

9 August 2017

Diane E Milenic

6

1 reference

Europe PubMed Central

9 August 2017

publication date

1 December 2011

1 reference

Europe PubMed Central

9 August 2017

Pharmaceuticals

1 reference

Europe PubMed Central

9 August 2017

5

1 reference

Europe PubMed Central

9 August 2017

1-15

1 reference

Europe PubMed Central

9 August 2017

1

1 reference

Europe PubMed Central

9 August 2017

copyright license

Creative Commons Attribution 4.0 International

22 December 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Preparation and biological evaluation of (177)Lu conjugated PR81 for radioimmunotherapy of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Trastuzumab: in HER2-positive metastatic gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Antibody-targeted radiation cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Protein measurement with the Folin phenol reagent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Targeting strategies for cancer radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

Human colonic adenocarcinoma cells. I. Establishment and description of a new line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

27 July 2018

The HER-2/neu oncogene in tumors of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.3390%2FPH5010001

21 January 2018

Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.

1 reference

https://api.crossref.org/works/10.3390%2FPH5010001

21 January 2018

Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.

1 reference

https://api.crossref.org/works/10.3390%2FPH5010001

21 January 2018

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

1 reference

https://api.crossref.org/works/10.3390%2FPH5010001

21 January 2018

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

1 reference

https://api.crossref.org/works/10.3390%2FPH5010001

21 January 2018

Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging

1 reference

https://api.crossref.org/works/10.3390%2FPH5010001

21 January 2018

Antibody guided precision radiation therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

25 September 2018

Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

25 September 2018

Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250925

25 September 2018

111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer

1 reference

https://api.crossref.org/works/10.3390%2FPH5010001

21 January 2018

Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2-positive metastatic breast cancer: trastuzumab and beyond

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22229017

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3390/PH5010001

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35650273&oldid=1868440119"